scholarly journals Isolated soya protein with standardised levels of isoflavones, cotyledon soya fibres and soya phospholipids improves plasma lipids in hypercholesterolaemia: a double-blind, placebo-controlled trial of a yoghurt formulation

2004 ◽  
Vol 91 (3) ◽  
pp. 393-401 ◽  
Author(s):  
Pekka Puska ◽  
Vesa Korpelainen ◽  
Lars H. Høie ◽  
Eva Skovlund ◽  
Knut T. Smerud
Keyword(s):  
Ldl Cholesterol ◽  
Intervention Group ◽  
Gastrointestinal Symptoms ◽  
Hdl Cholesterol ◽  
Dropout Rate ◽  
Soya Protein ◽  
Lipid Lowering ◽  
Control Group ◽  
Lowering Effect ◽  
Lipid Lowering Effect

The objective was to study whether a yoghurt containing isolated soya protein with standardised levels of isoflavones, cotyledon soya fibres and soya phospholipids is more effective in lowering total and LDL-cholesterol than a placebo. One hundred and forty-three subjects were randomised to the soya group (n69) or to the placebo (n74). The mean baseline levels were 7·6 and 5·1mmol/l for total and LDL-cholesterol, respectively. Fasting serum lipoproteins were assessed five times during the 8-week intervention period, and 4 weeks thereafter. The results were analysed by a mixed model for unbalanced repeated measurements. During the intervention, there were highly significant differences in lipid-lowering effect in favour of the active soya intervention group compared with the control group. The significant differences were for total cholesterol (estimated mean difference 0·40mmol/l;P<0·001), LDL-cholesterol (0·39mmol/l;P<0·001), non-HDL-cholesterol (0·40mmol/l;P<0·001) and for the total:HDL-cholesterol ratio (0·23;P=0·005). There was no difference in the effects on HDL-cholesterol, triacylglycerols or homocysteine. The lipid-lowering effect occurred within 1–2 weeks of intervention, and was not due to weight loss. The safety profile for active soya was similar to the placebo group, except for gastrointestinal symptoms, which caused a significantly higher dropout rate (fourteenv. three subjects) among the subjects taking active soya.

scholarly journals PROPHYLACTIC LIPID LOWERING EFFECTS OF AQUEOUS EXTRACT OF EMILIA PREATEMISSA ON CARBON TETRACHLORIDE (CCL4)-INDUCED HYPERLIPIDEMIC ALBINO RATS

2021 ◽  
pp. 13-16
Author(s):  
YEMISI RUFINA ALLI SMITH ◽  
BUKOLA TOLA ALUKO ◽  
SAMUEL IDOWU FAYOMI ◽  
OLAJUMOKE OMOLARA OJO
Keyword(s):  
Carbon Tetrachloride ◽  
Total Cholesterol ◽  
Aqueous Extract ◽  
Ldl Cholesterol ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Lipid Lowering ◽  
Control Group ◽  
Albino Rats ◽  
Hmgcoa Reductase

Objective: Hyperlipidemia has been described as one of the greatest risk factors contributing to the prevalence and severity of cardiovascular diseases which has been identified as a primary cause of death. This study evaluates the lipid-lowering effects of aqueous extract of Emilia praetermissa (EP) leaves. Methods: The investigation was carried out on rats induced with Carbon tetrachloride (CCl4 1 ml/kg body weight), pretreated with the aqueous extracts of Emilia praetermissa and then compared with a standard hypolipidemic drug, Simvastatin. The effects of Emilia praetermissa on the lipid profile were assessed by measuring the levels of total cholesterol, triglyceride, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol. The effect on HMGCoA Reductase and Lecithine Cholesterol Acyltransferase (LCAT), which are important enzymes in lipid metabolism were also evaluated in the plasma, liver and heart of albino rats. Results: Administration of 50, 100 and 200 mg/kg doses of aqueous extract of Emilia praetermissa leaves led to a significant reduction (P<0.05) in total cholesterol, LDL cholesterol, triglyceride levels and a significant increase (P<0.05) in HDL cholesterol in the tissues in a manner close to that of Normal and Standard control group. Emilia praetermissa aqueous extract led to a significant increase (P<0.05) in the activity of LCAT and inhibition of HMGCoA reductase. Conclusion: These results suggest that Emilia praetermissa leaves could play a cardioprotective role and probably serve as a new potential natural product for the management of hyperlipidema. Further investigations are warranted to elucidate the mechanism of its lipid-lowering action.

Cost of lipid lowering in patients with coronary artery disease by Case Method Learning

2005 ◽  
Vol 21 (2) ◽  
pp. 180-186 ◽  
Author(s):  
Anna Kiessling ◽  
Niklas Zethraeus ◽  
Peter Henriksson
Keyword(s):  
Primary Care ◽  
Coronary Artery Disease ◽  
Ldl Cholesterol ◽  
Intervention Group ◽  
Lipid Lowering ◽  
Control Group ◽  
Case Method ◽  
Artery Disease ◽  
The Cost

Objectives:This investigation was undertaken to study the costs of a Case Method Learning (CML) -supported lipid-lowering strategy in secondary prevention of coronary artery disease (CAD) in primary care.Methods:This prospective randomized controlled trial in primary care with an additional external specialist control group in Södertälje, Stockholm County, Sweden, included 255 consecutive patients with CAD. Guidelines were mailed to all general practitioners (GPs; n=54) and presented at a common lecture. GPs who were randomized to the intervention group participated in recurrent CML dialogues at their primary health-care centers during a 2-year period. A locally well-known cardiologist served as a facilitator. Assessment of low-density lipoprotein (LDL) cholesterol was performed at baseline and after 2 years. Analysis according to intention-to-treat—intervention and control groups (n=88)—was based on group affiliation at baseline. The marginal cost of lipid lowering comprised increased cost of lipid-lowering drugs in the intervention group compared with the primary care control group, cost of attendance of the GP's in the intervention group, and cost of time for preparation, travel, and seminars of the facilitator. Costs are as of 2002 with an exchange rate 1 US$=9.5 SEK (Swedish Crowns).Results:Patients in the primary care intervention group had their LDL cholesterol reduced by 0.5 (confidence interval [CI], 0.1–0.9) mmol/L compared with the primary care control group (p<.05). No change occurred in controls. LDL cholesterol in the external specialist control group decreased by 0.6 (CI, 0.4–0.8) mmol/L. The cost of the educational intervention represented only 2 percent of the drug cost. The cost of lipid lowering in the intervention group, including the cost of the educational intervention, was actually lower than that of patients treated at the specialist clinic—106 US$ per mmol decrease in LDL cholesterol in the intervention group and 153 US$ per mmol decrease in LDL cholesterol in the specialist group. EuroQol 5D Index, which gives an estimate of global health-related quality of life, was 0.80 (CI, 0.75–0.85) in the present cohort.Conclusions:The additional cost of CML was only 2 percent of the drug cost. Assuming the same gain in life expectancy per millimole decrease in LDL cholesterol as in the 4S-study gives a cost per gained quality-adjusted life year of US$ 24,000. This finding indicates that the CML-supported lipid-lowering strategy is cost-effective. The low cost of CML in primary care should probably warrant its use in the improvement of the quality of care in other major chronic diseases.

scholarly journals Effect of a novel functional tomato sauce (OsteoCol) from vine-ripened tomatoes on serum lipids in individuals with common hypercholesterolemia: tomato sauce and hypercholesterolemia

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Yvelise Ferro ◽  
Elisa Mazza ◽  
Elvira Angotti ◽  
Roberta Pujia ◽  
Angela Mirarchi ◽  
...  
Keyword(s):  
Serum Lipids ◽  
Ldl Cholesterol ◽  
Lipid Lowering ◽  
Carotenoid Content ◽  
Adherence Rate ◽  
Tomato Sauce ◽  
Lowering Effect ◽  
Significant Difference ◽  
High Adherence ◽  
Lipid Lowering Effect

Abstract Background Most studies focused on the benefits of lycopene on serum lipids but no studies have been specifically designed to assess the role of a tomato sauce from vine-ripened tomatoes on patients affected by polygenic hypercholesterolemia. The aim of this study was to compare the lipid-lowering effect of a novel functional tomato sauce with a well-known functional food with a lipid-lowering effect, i.e. a sterol-enriched yogurt. Methods In this cross-over study, we evaluated a population of 108 ambulatory patients affected by polygenic hypercholesterolemia of both gender, who were allocated to a tomato sauce (namely OsteoCol) 150 ml/day or a sterol-enriched yogurt (containing sterols 1.6 g/die) treatment, for 6 weeks. Carotenoids content was 3.5 mg per gram of product. We measured serum lipids and creatinine and transaminases at basal and follow-up visit. Results A total of 91 subjects completed the protocol. A significant difference in LDL-cholesterol change was found between participants taking yogurt, tomato sauce (high adherence) and tomato sauce (low adherence) (− 16; − 12; + 8 mg/dl respectively; p < 0.001). We found a greater LDL-cholesterol reduction in the participants with a basal LDL-cholesterol more than 152 mg/dl (15% for sterol-enriched yogurt and 12% for tomato sauce at high adherence). Conclusion A novel functional tomato sauce from vine-ripened tomatoes compares favourably with a commercialised sterol-enriched yogurt in term of absolute LDL-cholesterol change. Intake of a tomato sauce with a high carotenoid content may support treatment of patients affected by common hypercholesterolemia. The present study has various limitations. The presence of other dietary components, which may have influenced the results, cannot be ruled out. Of course, these results cannot be extrapolated to other populations. Furthermore, there was a low adherence rate in the tomato sauce group. Moreover, we did not report serum carotenoids data. Trial registration: ID: 13244115 on the ISRCTN registry, retrospectively registered in 2019-5-14. URL: http://www.isrctn.com/ISRCTN13244115

scholarly journals The Mediterranean Eating in Scotland Experience project: evaluation of an Internet-based intervention promoting the Mediterranean diet

2005 ◽  
Vol 94 (2) ◽  
pp. 290-298 ◽  
Author(s):  
Angeliki Papadaki ◽  
Jane A. Scott
Keyword(s):  
Nutrition Education ◽  
Mediterranean Diet ◽  
Intervention Group ◽  
Saturated Fat ◽  
Hdl Cholesterol ◽  
Control Group ◽  
Monounsaturated Fat ◽  
Feedback Intervention ◽  
Intention To Treat ◽  
The Mediterranean

A 6-month intervention study with a quasi-experimental design was conducted to evaluate the effectiveness of an Internet-based, stepwise, tailored-feedback intervention promoting four key components of the Mediterranean diet. Fifty-three (intervention group) and nineteen (control group) healthy females were recruited from the Universities of Glasgow and Glasgow Caledonian, Scotland, respectively. Participants in the intervention group received tailored dietary and psychosocial feedback and Internet nutrition education over a 6-month period, while participants in the control group were provided with minimal dietary feedback and general healthy-eating brochures. Internet education was provided via an innovative Mediterranean Eating Website. Dietary changes were assessed with 7 d estimated food diaries at baseline and 6 months, and data were analysed to calculate the Mediterranean Diet Score, a composite score based on the consumption of eight components of the traditional Mediterranean diet. The ‘intention-to-treat’ analyses showed that, at 6 months, participants in the intervention group had significantly increased their intake of vegetables, fruits and legumes, as well as the MUFA:saturated fatty acid ratio in their diet, and had significantly increased plasma HDL-cholesterol levels and a reduced ratio of total:HDL-cholesterol. Participants in the control group increased their intake of legumes but showed no other favourable significant changes compared with baseline. This Internet-based, tailored-feedback intervention promoting components of the Mediterranean diet holds promise in encouraging a greater consumption of plant foods, as well as increasing monounsaturated fat and decreasing saturated fat in the Scottish diet; it also shows that the Mediterranean diet can be adopted by healthy individuals in northern European countries.

Does chenodesoxycholic acid have a lipid lowering effect in primary hyperlipoproteinemia?

1976 ◽  
Vol 10 (2) ◽  
pp. 147-149 ◽  
Author(s):  
G. Schlierf ◽  
A. Stiehl ◽  
C. C. Heuck ◽  
P. D. Lang ◽  
P. Oster ◽  
...  
Keyword(s):  
Lipid Lowering ◽  
Lowering Effect ◽  
Lipid Lowering Effect

scholarly journals Lipid-lowering effect of tenofovir in HIV-infected patients

2010 ◽  
Vol 66 (3) ◽  
pp. 682-683 ◽  
Author(s):  
M. Fabbiani ◽  
L. Bracciale ◽  
M. Doino ◽  
L. Sidella ◽  
S. Farina ◽  
...  
Keyword(s):  
Lipid Lowering ◽  
Lowering Effect ◽  
Lipid Lowering Effect
Sign in / Sign up

Export Citation Format

Share Document